# Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia

> **NCT01338337** · PHASE2 · COMPLETED · sponsor: **Asociación Andaluza de Hematología y Hemoterapia** · enrollment: 40 (actual)

## Conditions studied

- Myelodysplastic Syndrome (MDS)

## Interventions

- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT01338337
- **Lead sponsor:** Asociación Andaluza de Hematología y Hemoterapia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2016-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01338337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01338337, "Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01338337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*